Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.

ABSTRACT:

Purpose

Effective treatment options are limited for patients with advanced (metastatic or unresectable) melanoma who progress after immune checkpoint inhibitors and targeted therapies. Adoptive cell therapy using tumor-infiltrating lymphocytes has demonstrated efficacy in advanced melanoma. Lifileucel is an autologous, centrally manufactured tumor-infiltrating lymphocyte product.

Methods

We conducted a phase II open-label, single-arm, multicenter study in patients with advanced melanoma who had been previously treated with checkpoint inhibitor(s) and BRAF ± MEK targeted agents. Lifileucel was produced from harvested tumor specimens in central Good Manufacturing Practice facilities using a streamlined 22-day process. Patients received a nonmyeloablative lymphodepletion regime

SUBMITTER: Sarnaik AA 

PROVIDER: S-EPMC8376325 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature